STOCK TITAN

EyePoint Pharmaceuticals, Inc. - EYPT STOCK NEWS

Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.

EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).

The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.

EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.

Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.

EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported significant financial growth for 2021, with net product revenues increasing by 70% to $35.3 million compared to $20.8 million in 2020. The company also highlighted positive eight-month data from the Phase 1 DAVIO trial of EYP-1901 for wet AMD, with Phase 2 trials expected to commence in Q3 2022. However, the company also reported a net loss of $58.4 million, up from $45.4 million the previous year, attributed to increased operating expenses. Cash reserves reached $211.6 million, providing operational funding into late 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.29%
Tags
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 10:30 a.m. ET. This presentation will highlight the company's commitment to developing innovative therapeutics for serious eye disorders. Investors can access a live webcast and an archived replay through the company website for 90 days post-event. EyePoint's pipeline includes EYP-1901, targeting wet age-related macular degeneration, utilizing its Durasert® technology for sustained drug delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced a conference call scheduled for March 3, 2022, at 8:30 a.m. ET, to discuss its Q4 and full-year 2021 financial results and corporate developments. Interested participants can join by calling (877) 312-7507 domestically or (631) 813-4828 internationally, using conference ID 5058194. This presentation will also be available via live audio webcast on the company's website, with a replay accessible post-event. EyePoint is focused on therapeutics to treat serious eye disorders, leveraging its Durasert® technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences earnings
Rhea-AI Summary

EyePoint Pharmaceuticals (EYPT) announced positive interim data from the Phase 1 DAVIO clinical trial of EYP-1901, an intravitreal anti-VEGF treatment for wet age-related macular degeneration (AMD). The results, presented by Dr. Jay Duker, indicate a strong safety profile with no serious adverse events reported. After eight months, 41% of patients did not need supplemental anti-VEGF injections, showcasing a significant 75% reduction in treatment burden. A Phase 2 trial is anticipated in Q3 2022, following FDA discussions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has released updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD, demonstrating positive safety and efficacy over eight months. A Phase 2 study is set to begin in Q3 2022 following a productive meeting with the FDA. In Q4 2021, customer demand for YUTIQ® and DEXYCU® surged by 16% and 5%, with cash reserves of approximately $210 million. Additionally, the company appointed Michael C. Pine as Chief Corporate Development and Strategy Officer, reinforcing its leadership as it pivots to retina-focused treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.56%
Tags
none
-
Rhea-AI Summary

EyePoint Pharmaceuticals, a leader in therapeutics for serious eye disorders, has appointed Michael C. Pine as Chief Corporate Development and Strategy Officer. Pine brings over 20 years of experience in the pharmaceutical sector, previously holding senior roles at Medexus, Lupin, Aralez, and Novartis. His expertise is expected to enhance EyePoint's corporate growth and strategic initiatives, particularly in advancing their product pipeline. In relation to Pine's appointment, 100,000 stock options were granted as part of his inducement award, adhering to Nasdaq guidelines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.56%
Tags
management
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an expanded partnership with ImprimisRx for the U.S. sales and marketing of DEXYCU®, effective January 1, 2022. ImprimisRx will absorb most of EyePoint’s DEXYCU commercial organization, enhancing its ability to promote the injectable steroid treatment for post-operative inflammation. EyePoint retains revenue recognition, manufacturing, and distribution responsibilities. The partnership aims to accelerate DEXYCU’s growth and improve treatment accessibility for patients in need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
none
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the closing of a public offering of 5,122,273 shares of common stock, including 1,095,000 shares purchased under the underwriter's option. The shares were priced at $13.75 each, with pre-funded warrants sold for $13.74 each, generating gross proceeds of approximately $115.4 million. The proceeds will support the Phase 2 clinical trials of EYP-1901 for wet AMD, DR, and RVO, along with earlier-stage pipeline initiatives. The offering was made under an SEC shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
-
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced an underwritten public offering of 4,027,273 shares at $13.75 each, alongside pre-funded warrants for 3,272,727 shares at $13.74 each, aiming for gross proceeds of approximately $100.3 million. The funds will primarily advance EYP-1901 into Phase 2 trials for wet AMD, DR, and RVO, and support pipeline initiatives. The offering is expected to close by November 19, 2021, pending customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.96%
Tags
Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced an underwritten public offering of $100 million in common stock, with an option for underwriters to purchase an additional $15 million. The offering aims to fund Phase 2 clinical trials for EYP-1901, targeting wet AMD, diabetic retinopathy, and retinal vein occlusion. The proceeds will also support earlier stage pipeline initiatives and general corporate purposes. The securities are offered under a previously filed registration statement, and the offering's completion is subject to market conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.96%
Tags

FAQ

What is the current stock price of EyePoint Pharmaceuticals (EYPT)?

The current stock price of EyePoint Pharmaceuticals (EYPT) is $7.33 as of December 24, 2024.

What is the market cap of EyePoint Pharmaceuticals (EYPT)?

The market cap of EyePoint Pharmaceuticals (EYPT) is approximately 500.3M.

What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?

EyePoint Pharmaceuticals specializes in developing and commercializing ophthalmic products aimed at treating serious retinal diseases using its proprietary sustained intraocular drug delivery system, Durasert®.

What is DURAVYU™?

DURAVYU™ (EYP-1901) is EyePoint's lead product candidate, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib with Durasert® technology.

Where is EyePoint Pharmaceuticals headquartered?

EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, USA.

What are the key products in EyePoint's pipeline?

Key products in EyePoint's pipeline include DURAVYU™ (EYP-1901), a TIE-2 agonist EYP-2301, and razuprotafib, all utilizing the Durasert® technology.

How did EyePoint Pharmaceuticals perform financially in 2023?

For the year ended December 31, 2023, EyePoint reported total net revenue of $46.0 million, driven by revenues from royalties and collaborations.

What is the Durasert® technology?

Durasert® is EyePoint's proprietary sustained intraocular drug delivery system designed to provide continuous therapeutic effects for extended periods.

Has EyePoint Pharmaceuticals received FDA approval for any products?

Yes, EyePoint has received FDA approval for products like RETISERT® and YUTIQ®, which are based on its Durasert® drug delivery technology.

What are the geographical operational footprints of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals operates in the U.S., China, and the UK.

What is EyePoint's strategy for future growth?

EyePoint's strategy involves advancing its clinical pipeline, securing strategic partnerships, and leveraging its proprietary Durasert® technology to address unmet medical needs in serious retinal diseases.

How does EyePoint Pharmaceuticals generate revenue?

EyePoint generates revenue primarily from royalties, collaborations, and product sales.

EyePoint Pharmaceuticals, Inc.

Nasdaq:EYPT

EYPT Rankings

EYPT Stock Data

500.28M
65.07M
1.14%
93.48%
14.47%
Biotechnology
Laboratory Analytical Instruments
Link
United States of America
WATERTOWN